European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
p16 and retinoblastoma protein expression in endometrial carcinoma and clinical significance
1 University of Douala, University Teaching Hospital Yaounde (Cameroon), 2Wuhan University, Hubei Medical Institute (China)
Eur. J. Gynaecol. Oncol. 2011, 32(3), 309–315;
Published: 10 June 2011
Objective: To investigate the clinical significance of p16 expression, a product of the cyclin dependent kinase inhibitor CDKN2 (also known as MTS1, multiple tumor suppressor 1) and assess its relationship with retinoblastoma protein expression in the pathogenesis of endometrial cancer. Method: p16 and pRb expression were histochemically evaluated, using p16 and RB polyclonal antibodies on paraffin sections of 27 primary endometrial adenocarcinomas with no therapy prior to surgery, through the streptavidin peroxydase conjugated method. Further analyses were carried out using the polymerase chain reaction for exon 1 gene amplification to investigate the mechanism of abnormal p16 expression. Result: p16 expression was detected in 100% of normal endometriums and in 74.04% of endometrial carcinomas (p < 0.05). This was significantly associated with tumor cell grade (p < 0.05). PCR analysis of exon 1 in five cases with no detectable p16 expression revealed four homozygous deletions. Additionally, the inverse correlation between RB and p16 expression was confirmed in this study, with 71.42% of tumors demonstrating inverse expression of p16 and RB (p < .005). Conclusion: p16 expression decrease is a significant event in endometrial carcinoma pathogenesis, and it is inversely correlated to tumor cell grade. Exon 1 homozygous deletion might be one of the mechanisms of loss of p16 expression. The p16/pRb growth suppressor pathway is targeted in human endometrial carcinoma.
Polymerase chain reaction